A federal judge in Louisiana declined to immediately block the FDA rule allowing the abortion drug mifepristone to be dispensed through the mail, but his 37-page ruling read less like a victory for the agency and more like a ticking clock. U.S. District Judge David Joseph granted the Trump administration's request to pause the case while the FDA conducts a safety review, then imposed hard deadlines and made clear the agency's leash is short.

The ruling, issued last week, came in a lawsuit filed in October 2025 by Louisiana Attorney General Liz Murrill and Rosalie Markezich, a woman who alleges her boyfriend ordered abortion drugs online from California and coerced her into taking them. The suit challenges the Biden-era FDA decision to let mifepristone be mailed directly to patients, arguing the agency violated the Administrative Procedure Act when it loosened longstanding safety requirements.

Judge Joseph, a Trump nominee, did not give Murrill the immediate injunction she wanted. But he did something arguably more consequential: he told the FDA, in writing, that Louisiana has standing to sue and is "likely to succeed" on the merits. That finding sets the stage for a far more aggressive ruling down the road if the agency drags its feet.

The FDA's deadline and the judge's warning

Joseph ordered the FDA to produce the entire administrative record of its safety decisions related to mifepristone within 60 days. The agency must file a status report within six months and notify the court within 14 days of completing its review. Breitbart News reported that the judge wrote pointedly about the limits of his patience.

In the ruling, Joseph stated:

"FDA has an obligation to act with all deliberate speed to review its past actions and complete a thorough analysis that addresses the deficiencies it has acknowledged. The parties and the American public deserve nothing less. Should the agency fail to complete its review and make any necessary revisions to the REMS within a reasonable timeframe, the Court's analysis, and the weight accorded to these factors, will inevitably change."

That is not the language of a judge who plans to let this case quietly expire.

The REMS, Risk Evaluation and Mitigation Strategies, is the FDA's framework for managing drugs with known safety risks. The 2023 version of the mifepristone REMS, finalized under the Biden administration, eliminated the requirement that the drug be dispensed in person and opened the door to mail-order distribution nationwide. Joseph's ruling suggests the agency approved those changes on thin evidence and for political reasons.

Evidence of a political end-run

The most striking section of the ruling concerns the judge's assessment of why the FDA acted as it did. Joseph wrote that in the post-Dobbs regulatory environment, "there is evidence that the 2023 REMS was approved without adequate consideration, at least in part, as part of an effort to circumvent anti-abortion states' ability to regulate abortion."

He continued:

"Likewise, there is evidence that the consequences of this action were predictable, out-of-state providers and related entities would expand access to mifepristone in ways designed to reach into jurisdictions like Louisiana. These actions cause concrete and ongoing injury to Louisiana..."

That assessment lines up with what pro-life advocates have argued for years: that the Biden FDA deliberately weakened mifepristone safeguards to create a workaround after the Supreme Court's 2022 Dobbs decision returned abortion regulation to the states. Blue-state shield laws combined with the FDA's mail-order rule allowed abortion pills to flow into states that had enacted protections for the unborn.

The Trump administration has already begun reversing Biden-era abortion drug policies at HHS, but the 2023 REMS remains in effect while the FDA review proceeds.

The Washington Times reported that Joseph criticized the Biden administration's 2023 decision to lift in-person dispensing requirements as based on a "dearth of information", a damaging characterization of an agency that claims to operate on rigorous science.

The long road to this courtroom

The regulatory history matters. In 2016, the FDA changed mifepristone's reporting requirements so that prescribers were only obligated to report patient fatalities, not serious adverse events short of death. In 2021, the Biden FDA went further and removed the in-person dispensing requirement entirely, allowing the drug to be sent through the mail. The agency made that change permanent in 2023.

After Dobbs, a separate legal challenge brought by doctors sought to block the mail-order rule. In 2024, the Supreme Court declined to do so, ruling that the physicians who brought the case lacked standing. The Court did not address the merits of the challenge, a point that left the underlying legal questions unresolved.

Louisiana's lawsuit, filed months later, appears to have cleared the standing hurdle that tripped up the earlier case. Judge Joseph found that the state itself suffers concrete injury from the rule, including Medicaid emergency-care costs imposed when complications arise from mifepristone use.

Meanwhile, pro-life organizations have pressed Attorney General Pam Bondi to enforce the Comstock Act against abortion pill distributors, adding another legal front to the fight over mail-order access.

The numbers behind the fight

The stakes are not abstract. Medication abortions now account for 63 percent of all abortions within the formal U.S. healthcare system. A 2025 report indicated an estimated 1.1 million abortions occurred last year. Telehealth abortions alone contributed tens of thousands of procedures in states that restrict abortion, a direct consequence of the mail-order rule Louisiana is challenging.

A 2025 study cited in the litigation suggested that serious adverse health events from mifepristone are far higher than previously reported. The FDA's own decision to narrow adverse-event reporting requirements back in 2016 means the agency may have been flying partially blind on safety data for nearly a decade.

Fox News reported that HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary asked their agencies to conduct a comprehensive safety review of the 2023 mifepristone REMS, a signal that the current administration takes the safety concerns seriously. Joseph wrote that "the completion of FDA's promised good faith, evidence-based, and expeditious review of the mifepristone REMS, not 'government by lawsuit,'" is what he considers to be in the public interest.

Murrill signals an appeal

Louisiana's attorney general did not accept the partial result quietly. Murrill said in a statement that the judge "concluded that Louisiana suffers irreparable harm every day" the 2023 REMS remains in effect, and she indicated she would ask an appeals court to pause the FDA's mail-order abortion rule while the review unfolds.

Her frustration is understandable. From Louisiana's perspective, every day the rule stays on the books is another day that out-of-state providers can mail abortion drugs into a state that has chosen to protect unborn life. The judge acknowledged as much, he simply decided to give the Trump administration's FDA a chance to fix the problem before wielding the judicial hammer.

The Trump administration itself sought the delay in this lawsuit, asking the court for time to let the FDA complete its review rather than face an immediate injunction. That strategy carries risk: if the FDA's review produces only cosmetic changes, the administration will have spent months of goodwill for nothing, and the judge has already telegraphed what happens next.

Just The News noted that Joseph's ruling criticized multiple aspects of the FDA's earlier loosening of safeguards, including the removal of in-person prescribing requirements, expansion of the gestational window for use, permission for non-doctors to prescribe, and reduced adverse-event reporting. The breadth of that criticism suggests the judge is prepared to act broadly if the agency's review falls short.

What comes next

The case now enters a holding pattern, but not an indefinite one. The FDA has 60 days to hand over its administrative record and six months to report on the status of its review. If the agency meets those deadlines with a genuine, evidence-based reassessment, the court may allow the process to play out. If it stalls or produces a whitewash, Joseph has made clear the calculus changes.

The broader pattern is familiar. Federal agencies under the Biden administration repeatedly used regulatory action to achieve policy goals that Congress never authorized and voters in many states explicitly rejected. The Dobbs decision was supposed to return abortion policy to the democratic process. The FDA's mail-order rule was an attempt to override that return, and a federal courtroom is once again the place where the limits of agency power get tested.

Judge Joseph gave the FDA a chance to do the right thing on its own. The question now is whether the agency will take that chance, or force the court to do it for them.